Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

Alex Renner, Mauricio Burotto, Jose Miguel Valdes, Juan Carlos Roman, Annerleim Walton-Diaz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.

Original languageEnglish
Pages (from-to)17562872211029779
JournalTherapeutic Advances in Urology
Volume13
DOIs
StatePublished - 23 Jul 2021

Bibliographical note

Publisher Copyright:
© The Author(s), 2021.

Keywords

  • bladder cancer
  • immune checkpoint inhibitor
  • immunotherapy
  • muscle invasive
  • neoadjuvant

Fingerprint

Dive into the research topics of 'Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?'. Together they form a unique fingerprint.

Cite this